Confirmatory assay development

The safe concentration of drug-related residue must be known in order to determine the withdrawal period for a veterinary product. Often the toxicity data is incomplete and an estimate must be made to progress with requisite residue studies. One approach is to conduct a total residue study with sufficiently widely-spaced sacrifice intervals to assess the rate of depletion of total residue over the projected range of probable safe concentrations. A zero-withdrawal sacrifice interval should be included. The target tissue and marker residue are identified and surveillance/confirmatory assays developed. If a major portion of residue is non-extractable (bound) and the marker is undetectable at times when total residue is still significant, a residue bioavailability study may be necessary. To complete the data package, final residue and comparative metabolism studies are conducted. Studies on the metabolism of flunixin in cattle will illustrate this approach. 

For confirmatory assay, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is becoming more frequently used in the analysis of OTC owing to its high sensitivity and ability. Electrospray ionization (ESI) [55-57] and atmospheric pressure chemical ionization (APCI) [41] methods combined with tandem mass spectrometry are favored because of their higher sensitivity and better reproducibility. Hamscher et al. [58] developed a method for the determination of persistent TC residues in soil fertilized with manure by HPLC tandem mass spectrometry, MS-MS, and confirmation by MS-MS-MS. Zhu et al. [59] developed an LC-tandem mass spectrometry for the analysis of common tetracyclines in water. The detection limit for oxytetracycline was 0.21 pg/L. Lykkeberg et al. [60] used LC-MS/MS for determination of oxytetracycline and its impurities EOTC, TC, ETC, ADOTC, oc-AOTC, and /i-AOTC. 

A positive result from a eukaryotic reporter assay would lower the ranking of a compound for development, alert lead optimization chemists and similarly trigger a confirmatory assay and alert safety assessment. 

The use of alkaloids as therapeutic drugs, drugs of abuse and deliberate poisons has required the development of screening and confirmatory assays for these... 

A positive result from a bacterial reporter assay would lower the ranking of the compound for development. The compound file should be aimotated with an alert for a confirmatory in vitro test (if the compound remains hve), in this case it might be a screening Ames at a later stage. There should also be a second alert to the lead optimization chemists. A third alert should still notify the genotoxicity safety assessment team that the compound is a priority for mechanistic investigation if the series continues, with the associated need for coordination of in vivo studies, this would be a lower priority than an Ames profiling positive. 

In some disorders there is a clearly recognisable phenotype, often a named syndrome that has later been linked to a specific biochemical cause. However, once the biochemical basis of such a syndrome has been recognised it often becomes apparent that milder variants, formes frustes showing only some of the features of the classical syndrome, are relatively common. The diagnostic assay then changes from being a rarely used confirmatory test to one that is requested relatively frequently for a variety of less specific indications. The same phenomenon is seen where the abnormal phenotype develops progressively, as in most of the lysosomal disorders, and a bat-... 

Confirmatory methods based on LC-TSP-MS have further been developed for the determination of various penicillin derivatives, penicillin G, and cephapirin and its metabolite in milk. In the assay for penicillin derivatives (97), ammonium acetate buffer replaced the ion-pair reagents used in the mobile phase, whereas the positive-ion TSP mass spectra of penicillins displayed both MU and MNa ions, which provided unequivocal proof of the suspected drug residue. The detection limits in this assay were estimated to be in the range of 100-200 ppb. A detection limit of 100 ppb was also observed in one of the assays of penicillin G in milk (98), although another assay (99) offered a detection limit of only 3 ppb. Tills was probably due to the fact that only ultrafiltration was employed for milk cleanup in the former assay, while both protein precipitation and solid-phase cleanup were used in the latter. In the case of the cephapirin analysis (100), the principal metabolite in milk was identified as deacetylcephapirin by both LC-PDA detection and LC-TSP-MS. In the LC-MS method, the detection limits for cephapirin and deacetylcephapirin were 100 and 50 ppb, respectively. 

The interpretation of the term maybe present in terms of the statistical confidence in the screening test result depends on the performance characteristics of the assay and the verification of reliable performance by a body of actual test application data. Nonetheless, the confirmation that the test substance actually is present in the sample requires independent determination. For method development purposes, screening tests should be considered a part of an analytical system for a given substance, where the complete system consists of a separate confirmatory technique to verify the initial screening result. 

When appropriate, a dynamic (in-use) method evaluation of the assay will be performed following completion of the EMSL-LV single laboratory evaluation or confirmation. This type of evaluation is intended for immunoassays that are well-characterized and mature (i.e., a method where the developer has extensive performance data regarding matrix effects, cleanup, cross-reactivity, confirmatory analyses, and any other pertinent information). The data obtained during the dynamic evaluation will actually be used in a monitoring program. A dynamic evaluation can occur only where there is an immediate and urgent need for an analytical method. 

Although other workers have prepared and used antisera in immuno-fiuorescence studies, confirmatory reports of the practicability of preparing antisera suitable for radioimmunoassays have not yet appeared. A considerable degree of cross-reactivity between species, both in the effects of administered hormone and in hormone-antibody interactions, appears to be a feature of most thyrocalcitonin preparations so far studied. Although this partial lack of species specificity should facilitate the development of antisera and of isotopically labeled hormone preparations from animals for use in immunoassays in man, it must also leave some doubt with respect to the specificity of such assays when applied to so complex a mixture as blood plasma. 

Once this initial characterization has been completed, continuation of the microscopic analysis using the hot-stage accessory may proceed. As an initial analysis, the ramp rate utilized for the DSC experiment should also be used for the hot-stage analysis. Use of a consistent ramp rate permits direct comparison of the data previously collected by DSC and TGA. If transitions are observed in the thermal data up to 300°C, the hot-stage experiment should also be run to that temperature. Ultimately, the assay should be conducted to generate confirmatory data on all transitions of interest. If available, the color camera should be utilized so that images may be collected as documentation of the transitions observed. Once the experiment is completed, the analyst may be able to compare the DSC, TGA, XRD, optical, and HSM data and develop a comprehensive characterization of the material. 

The acquired immune deficiency syndrome (AIDS) marks another challenge in immune research. In Austria, an indirect AIDS-immunofluorescence assay has been developed by Waldheim Pharmaceutical Co. It has been approved by the US Food and Drug Administration since 1992 and is mainly recommended as a confirmatory test. 

FIGURE 6.1 Conceptual diagram of fit for purpose biomarkers method validation. The method validation processes include four activity circles prevalidation (preanalytical consid eration and method development), exploratory method validation, in study method validation and advanced method validation. The processes are continuous and iterative, dictated by the purpose of the biomarker application. The solid arrows depict the normal flow of biomarker development (prevalidation), method validation (exploratory or advanced), and application (in study method validation). The process could include moving the chosen biomarkers from exploratory mechanistic pilot studies to advanced validation and confirmatory studies, or from exploratory validation to advanced validation after changes in critical business decision. The broken arrows represent scenarios where validation data do not satisfy study requirements, necessitating assay refinement or modification. 

The scarcity of purified ciguatoxin standards and the challenging nature of analyses for ciguatoxins in fish tissues precluded development or adoption of ciguatoxin methods in most laboratories. While many are certainly capable, only a few laboratories have produced the necessary standards and sustained support required for development and routine application of screening assays and confirmatory analyses for ciguatera toxins. Protocols for in vitro assay and LC-MS/MS analysis of fish tissues have been developed in U.S. Food and Drug Administration (FDA) and National Oceanic and Atmospheric Administration (NOAA) laboratories. Laboratories in Japan (T. Yasumoto) and Australia (R. Lewis) use similar protocols that predate those in the United States. 

---